Brian Marples

Dr. Brian Marples

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Physics in Medicine & Biology
Verified
Journal Article
Open access
FVFrank Verhaegen
Frank Verhaegen
Karl ButterworthKarl Butterworth
Karl Butterworth
ACAnthony Chalmers
Anthony Chalmers
RCRob P. Coppes
Rob P. Coppes
DRDirk de Ruysscher
Dirk de Ruysscher
Ludwig DuboisLudwig Dubois
Ludwig Dubois
This Roadmap paper covers the field of precision preclinical x-ray radiation studies in animal models. It is mostly focused on models for cancer and normal tissue response to radiation, but also discusses other disease models. The recent technological evolution in imaging, irradiation, dosimetry and monitoring that have empowered these kinds of studies is discussed, and many developments in the near future are outlined. Finally, clinical translation and reverse translation are discussed.

6 May 2010 in Medical Physics
Verified
Journal Article
Closed access
MJMichael C. Joiner
Michael C. Joiner
NMNagaraju Mogili
Nagaraju Mogili
BMBrian Marples
Brian Marples
JBJay Burmeister
Jay Burmeister

15 March 2021 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
ANIS AHMADANIS AHMAD
ANIS AHMAD
Junwei ShiJunwei Shi
Junwei Shi
SASaba Ansari
Saba Ansari
JAJumana Afaghani
Jumana Afaghani
JMJudith Molina
Judith Molina
BMBrian Marples
Brian Marples
The kidney is a radiosensitive late-responding normal tissue. Injury is characterized by radiation nephropathy and decline of glomerular filtration rate (GFR). The current study aimed to compare tw...

1 November 2021 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
BWBrendan S. Whitelaw
Brendan S. Whitelaw
STSean Tanny
Sean Tanny
CJCarl J. Johnston
Carl J. Johnston
AMAnia K. Majewska
Ania K. Majewska
MOM. Kerry O'BAnion
M. Kerry O'BAnion
BMBrian Marples
Brian Marples

12 May 2023 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
NRNatalie R. Ricciardi
Natalie R. Ricciardi
FMFarzaneh Modarresi
Farzaneh Modarresi
ILInes Lohse
Ines Lohse
NANadja S. Andrade
Nadja S. Andrade
INIan R. Newman
Ian R. Newman
Claude-Henry VolmarClaude-Henry Volmar
Claude-Henry Volmar
We have previously shown that histone deacetylase (HDAC) inhibition and cranial radiotherapy (RT) independently improve molecular and behavioral Alzheimer’s disease (AD)-like phenotypes. In the present study, we investigate the synergistic potential of using both RT and HDACi as a low-dose combination therapy (LDCT) to maximize disease modification (reduce neuroinflammation and amyloidogenic APP processing, increase neurotrophic gene expression) while minimizing the potential for treatment-associated side effects.LDCT consisted of daily administration of the HDAC3 inhibitor RGFP966 and/or bi-weekly cranial x-irradiation. Amyloid-beta precursor protein (APP) processing and innate immune response to LDCT were assessed in vitro and in vivo using human and murine cell models and 3xTg-AD mice. After 2 months of LDCT in mice, behavioral analyses as well as expression and modification of key AD-related targets (Aβ, tau, Csf1r, Bdnf, etc.) were assessed in the hippocampus (HIP) and prefrontal cortex (PFC).LDCT induced a tolerant, anti-inflammatory innate immune response in microglia and increased non-amyloidogenic APP processing in vitro. Both RT and LDCT improved the rate of learning and spatial memory in the Barnes maze test. LDCT induced a unique anti-AD HIP gene expression profile that included upregulation of neurotrophic genes and downregulation of inflammation-related genes. RT lowered HIP Aβ42/40 ratio and Bace1 protein, while LDCT lowered PFC p-tau181 and HIP Bace1 levels.Our study supports the rationale for combining complementary therapeutic approaches at low doses to target multifactorial AD pathology synergistically. Namely, LDCT with RGFP966 and cranial RT shows disease-modifying potential against a wide range of AD-related hallmarks.

18 July 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ANIS AHMADANIS AHMAD
ANIS AHMAD
Junwei ShiJunwei Shi
Junwei Shi
SASaba Ansari
Saba Ansari
SMSandra Merscher
Sandra Merscher
APAlan Pollack
Alan Pollack
BMBrian Marples
Brian Marples